357 related articles for article (PubMed ID: 30769193)
21.
Ruff A; Ballard HJ; Pantel AR; Namoglu EC; Hughes ME; Nasta SD; Chong EA; Bagg A; Ruella M; Farwell MD; Svoboda J; Sellmyer MA
Mol Imaging Biol; 2021 Dec; 23(6):818-826. PubMed ID: 34231105
[TBL] [Abstract][Full Text] [Related]
22. To Determine the Prognostic Significance of 18-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Scan-Derived Parameters (Total Lesion Glycolysis and Metabolic Tumor Volume) in Patients of Diffuse Large B-Cell Lymphoma with Only Nodal Involvement.
Gupta N; Singh N
Indian J Nucl Med; 2020; 35(2):100-104. PubMed ID: 32351262
[TBL] [Abstract][Full Text] [Related]
23. Validation of a Multifocal Segmentation Method for Measuring Metabolic Tumor Volume in Hodgkin Lymphoma.
Camacho MR; Etchebehere E; Tardelli N; Delamain MT; Vercosa AFA; Takahashi MES; Brunetto SQ; Metze IGHL; Souza CA; Cerci JJ; Ramos CD
J Nucl Med Technol; 2020 Mar; 48(1):30-35. PubMed ID: 31604902
[TBL] [Abstract][Full Text] [Related]
24. Metabolic tumor burden on baseline
Chen S; He K; Feng F; Wang S; Yin Y; Fu H; Wang H
Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1830-1839. PubMed ID: 31187163
[TBL] [Abstract][Full Text] [Related]
25. The contribution of metabolic parameters of FDG PET/CT prior and during therapy of adult patients with lymphomas.
Prieto Prieto JC; Vallejo Casas JA; Hatzimichael E; Fotopoulos A; Kiortsis DN; Sioka C
Ann Nucl Med; 2020 Oct; 34(10):707-717. PubMed ID: 32924071
[TBL] [Abstract][Full Text] [Related]
26. Volumetric parameters of 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography/computed tomography can predict histopathologic treatment response after neoadjuvant chemoradiotherapy in pancreatic adenocarcinoma.
Sakane M; Tatsumi M; Hori M; Onishi H; Tsuboyama T; Nakamoto A; Ota T; Eguchi H; Wakasa K; Hatazawa J; Tomiyama N
Eur J Radiol; 2017 Sep; 94():64-69. PubMed ID: 28712692
[TBL] [Abstract][Full Text] [Related]
27. Early positron emission tomography/computed tomography as a predictor of response after CTL019 chimeric antigen receptor -T-cell therapy in B-cell non-Hodgkin lymphomas.
Shah NN; Nagle SJ; Torigian DA; Farwell MD; Hwang WT; Frey N; Nasta SD; Landsburg D; Mato A; June CH; Schuster SJ; Porter DL; Svoboda J
Cytotherapy; 2018 Dec; 20(12):1415-1418. PubMed ID: 30385043
[TBL] [Abstract][Full Text] [Related]
28. Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis measured by 18F-FDG PET/CT in salivary gland carcinomas.
Ryu IS; Kim JS; Roh JL; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
J Nucl Med; 2013 Jul; 54(7):1032-8. PubMed ID: 23670902
[TBL] [Abstract][Full Text] [Related]
29. Role of Various Metabolic Parameters Derived From Baseline 18F-FDG PET/CT as Prognostic Markers in Non-Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy.
Sharma A; Mohan A; Bhalla AS; Sharma MC; Vishnubhatla S; Das CJ; Pandey AK; Sekhar Bal C; Patel CD; Sharma P; Agarwal KK; Kumar R
Clin Nucl Med; 2018 Jan; 43(1):e8-e17. PubMed ID: 29112011
[TBL] [Abstract][Full Text] [Related]
30. Dual-Energy Computed Tomography-Based Iodine Quantitation for Response Evaluation of Lung Cancers to Chemoradiotherapy/Radiotherapy: A Comparison With Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography-Based Positron Emission Tomography/Computed Tomography Response Evaluation Criterion in Solid Tumors.
Ren Y; Jiao Y; Ge W; Zhang L; Hua Y; Li C; Zhai W; Tang X; He W; Fang M; Zheng X
J Comput Assist Tomogr; 2018; 42(4):614-622. PubMed ID: 29613988
[TBL] [Abstract][Full Text] [Related]
31. Metabolic tumour volume and total lesion glycolysis, measured using preoperative 18F-FDG PET/CT, predict the recurrence of endometrial cancer.
Shim SH; Kim DY; Lee DY; Lee SW; Park JY; Lee JJ; Kim JH; Kim YM; Kim YT; Nam JH
BJOG; 2014 Aug; 121(9):1097-106; discussion 1106. PubMed ID: 24397772
[TBL] [Abstract][Full Text] [Related]
32. Whole Body Metabolic Tumor Volume and Total Lesion Glycolysis Predict Survival in Patients with Adrenocortical Carcinoma.
Satoh K; Patel D; Dieckmann W; Nilubol N; Kebebew E
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S714-20. PubMed ID: 26282908
[TBL] [Abstract][Full Text] [Related]
33. Functional Parameters of
Yang J; Zhu S; Pang F; Xu M; Dong Y; Hao J; Ma X
Contrast Media Mol Imaging; 2018; 2018():8659826. PubMed ID: 30363729
[TBL] [Abstract][Full Text] [Related]
34. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer.
Chen HH; Chiu NT; Su WC; Guo HR; Lee BF
Radiology; 2012 Aug; 264(2):559-66. PubMed ID: 22692034
[TBL] [Abstract][Full Text] [Related]
35. Imaging Biomarkers to Predict Outcomes in Patients With Large B-Cell Lymphoma With a Day 28 Partial Response by
Lutfi F; Goloubeva O; Kowatli A; Gryaznov A; Kim DW; Dureja R; Margiotta P; Matsumoto LR; Bukhari A; Ahmed N; Mushtaq MU; Law JY; Lee ST; Kocoglu MH; Atanackovic D; Yared JA; Hardy NM; McGuirk JP; Rapoport AP; Chen W; Dahiya S
Clin Lymphoma Myeloma Leuk; 2023 Oct; 23(10):757-763. PubMed ID: 37453865
[TBL] [Abstract][Full Text] [Related]
36. Metabolic PET/CT analysis of aggressive Non-Hodgkin lymphoma prior to Axicabtagene Ciloleucel CAR-T infusion: predictors of progressive disease, survival, and toxicity.
Breen WG; Young JR; Hathcock MA; Kowalchuk RO; Thorpe MP; Bansal R; Khurana A; Bennani NN; Paludo J; Bisneto JV; Wang Y; Ansell SM; Peterson JL; Johnston PB; Lester SC; Lin Y
Blood Cancer J; 2023 Aug; 13(1):127. PubMed ID: 37591834
[TBL] [Abstract][Full Text] [Related]
37. Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphoma.
Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
Eur J Haematol; 2015 Jun; 94(6):532-9. PubMed ID: 25311082
[TBL] [Abstract][Full Text] [Related]
38. Optimization of Metabolic Tumor Volume as a Prognostic Marker in CAR T-Cell Therapy for Aggressive Large B-cell NHL.
Rojek AE; Kline JP; Feinberg N; Appelbaum DE; Pu Y; Derman BA; Jakubowiak A; Kosuri S; Liu H; Nawas MT; Smith SM; Bishop MR; Riedell PA
Clin Lymphoma Myeloma Leuk; 2024 Feb; 24(2):83-93. PubMed ID: 37827881
[TBL] [Abstract][Full Text] [Related]
39. Volume-based quantitative FDG PET/CT metrics and their association with optimal debulking and progression-free survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery.
Vargas HA; Burger IA; Goldman DA; Miccò M; Sosa RE; Weber W; Chi DS; Hricak H; Sala E
Eur Radiol; 2015 Nov; 25(11):3348-53. PubMed ID: 25916387
[TBL] [Abstract][Full Text] [Related]
40. Individual Patient Data Meta-Analysis from 16 Trials for Safety Factors in Cytokine Release Syndrome After CAR-T Therapy in Patients with Non-Hodgkin Lymphoma (NHL) and Acute Lymphoblastic Leukemia.
Li J; Wu Z; Zhao N
Adv Ther; 2019 Oct; 36(10):2881-2894. PubMed ID: 31428935
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
